Bevacizumab, ZERIBEV® (Pfizer)/AVASTIN® (Roche) 25 mg/ml ®, is a recombinant humanised monoclonal IgG1 antibody It seems interesting to use bevacizumab in severe patients infected with SARS-CoV-2 requiring hospitalization in conventional unit or in ICU. This protocol CORIMUNO19-BEVA will evaluate the efficacy and safety of AVASTIN®/ ZERIBEV® (bevacizumab) COVID-19 patients hospitalized in conventional units. This phase 2 randomized clinical trial aimed at evaluating the efficacy and safety of AVASTIN®/ ZERIBEV® (bevacizumab) alone versus standard of care (SoC) in patients hospitalized in conventional units.
Drug: Bevacizumab Injection
Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.
Inclusion Criteria:
- Patients Requiring more than 3L/min of oxygen
- WHO progression scale = 5 to 8
Exclusion Criteria:
- Patients in 9 WHO progression class
- Patients with exclusion criteria to the CORIMUNO-19 cohort.
- Hypersensitivity to Bevacizumab or to any of their excipients.
- Pregnancy
- Active Cancer with undergoing treatment
- Oxygen patient requiring long-term oxygen before hospitalization
- Patient already included in a therapeutic trial; however, inclusion should be
discussed case by case with the trial coordinator.
- Contraindication to bevacizumab, risk of bleeding especially hemoptysis, active venous
or arterial thromboembolic disease and recent surgery.
- Hypersensitivity to the active substance or one of the excipients
Jacques Cadranel, MD PhD
1 56 01 66 73 - 33
jacques.cadranel@aphp.fr